Sequins As Novel Internal Controls to Improve Genomic Analysis
|
By LabMedica International staff writers Posted on 16 Aug 2016 |

Image: Sequins are small stretches of synthetic DNA to be added as a standardization control to a DNA sample during sequencing, helping analyze the large data files generated for genomic analysis. The technology is based on the notion of mirror image DNA. Sequins are essentially “mirror” images of natural DNA sequences. They behave like natural DNA sequences but can be easily recognized as synthetic (Photo courtesy of Chris Hammang, Garvan Institute of Medical Research).
Researchers have developed an intuitive technology called “Sequins” – synthetic “mirror” DNA sequences that reflect the human genome and can be used to better map, navigate, and analyze complexity within the genome. Currently human genome Sequins are freely available for research.
Scientists at the Garvan Institute of Medical Research (Darlinghurst, Sydney, NSW, Australia) developed the new technology. “Human genome sequencing is transforming biomedical research and healthcare,” said Dr. Tim Mercer, who led the development of Sequins, “And as genome sequencing is being increasingly used to diagnose disease, it is more important than ever that researchers and clinicians understand the accuracy of the genomic data they are looking at.”
Dr. Mercer and his team came up with the idea of adding Sequins, small stretches of synthetic DNA, to a patient’s DNA sample during sequencing. These Sequins (or sequencing spike-ins) then act as internal standards, helping researchers analyze the large data files generated during genome sequencing. The technology is based on an intuitively simple concept: the notion of mirror image DNA. “Sequins are, essentially, mirror images of natural DNA sequences. Like us, the genome has a ‘handedness’, and just as our right hand differs from our left hand, sequins differ from natural genome sequences. So sequins behave just like natural genome sequences, but they can be easily recognized as synthetic,” said Dr. Mercer.
When added to a sequencing reaction, sequins provide internal controls with which to assess the sensitivity and accuracy of genome sequencing. “A whole series of steps, first in the lab and then on the computer, are required to sequence a person’s genome or the genes that are expressed in different cells. Sequins are with the person’s DNA every step of the way: responding just as real DNA does at each step, yet unmistakably different from that real DNA. This allows a scientist to assess, and optimize, these different steps.”
Because sequins are added to each individual sample, they can provide a sample-by-sample assessment – something that has not previously been possible. “Sequins are the first technology to allow diagnostic statistics to be applied to each individual genome sequencing test,” said Dr. Mercer, “and we anticipate that their use will improve the reliability and sensitivity of genetic disease diagnosis.”
Cancer diagnosis is one area in which using Sequins should lead to improvements. “Incorporating Sequins into clinical tests for cancer diagnosis will increase the reliability of an individual diagnostic readout, reducing incorrect diagnoses and giving clinicians greater confidence in deciding the best course of treatment for their patient,” said Dr. Mercer.
Using Sequins will also make it possible to directly compare genomic data from research institutes and sequencing centers worldwide. “Sequins bring DNA sequencing to clinical standard, and will be an essential platform for genomic research and medicine,” said co-author Prof. John Mattick, Garvan’s executive director, “This is another important step in advancing Garvan’s mission to bring genomics to the clinic.”
The potential applications of Sequins are many. Because all genomes, from bacteria to human, have handedness, sequins can be similarly designed for any organism, or for almost any next-generation sequencing (NGS) application.
The Sequins technology is described in two linked studies, by Hardwick SA et al and by Deveson IW et al, both published August 8, 2016, in the journal Nature Methods.
Related Links:
Garvan Institute of Medical Research
Scientists at the Garvan Institute of Medical Research (Darlinghurst, Sydney, NSW, Australia) developed the new technology. “Human genome sequencing is transforming biomedical research and healthcare,” said Dr. Tim Mercer, who led the development of Sequins, “And as genome sequencing is being increasingly used to diagnose disease, it is more important than ever that researchers and clinicians understand the accuracy of the genomic data they are looking at.”
Dr. Mercer and his team came up with the idea of adding Sequins, small stretches of synthetic DNA, to a patient’s DNA sample during sequencing. These Sequins (or sequencing spike-ins) then act as internal standards, helping researchers analyze the large data files generated during genome sequencing. The technology is based on an intuitively simple concept: the notion of mirror image DNA. “Sequins are, essentially, mirror images of natural DNA sequences. Like us, the genome has a ‘handedness’, and just as our right hand differs from our left hand, sequins differ from natural genome sequences. So sequins behave just like natural genome sequences, but they can be easily recognized as synthetic,” said Dr. Mercer.
When added to a sequencing reaction, sequins provide internal controls with which to assess the sensitivity and accuracy of genome sequencing. “A whole series of steps, first in the lab and then on the computer, are required to sequence a person’s genome or the genes that are expressed in different cells. Sequins are with the person’s DNA every step of the way: responding just as real DNA does at each step, yet unmistakably different from that real DNA. This allows a scientist to assess, and optimize, these different steps.”
Because sequins are added to each individual sample, they can provide a sample-by-sample assessment – something that has not previously been possible. “Sequins are the first technology to allow diagnostic statistics to be applied to each individual genome sequencing test,” said Dr. Mercer, “and we anticipate that their use will improve the reliability and sensitivity of genetic disease diagnosis.”
Cancer diagnosis is one area in which using Sequins should lead to improvements. “Incorporating Sequins into clinical tests for cancer diagnosis will increase the reliability of an individual diagnostic readout, reducing incorrect diagnoses and giving clinicians greater confidence in deciding the best course of treatment for their patient,” said Dr. Mercer.
Using Sequins will also make it possible to directly compare genomic data from research institutes and sequencing centers worldwide. “Sequins bring DNA sequencing to clinical standard, and will be an essential platform for genomic research and medicine,” said co-author Prof. John Mattick, Garvan’s executive director, “This is another important step in advancing Garvan’s mission to bring genomics to the clinic.”
The potential applications of Sequins are many. Because all genomes, from bacteria to human, have handedness, sequins can be similarly designed for any organism, or for almost any next-generation sequencing (NGS) application.
The Sequins technology is described in two linked studies, by Hardwick SA et al and by Deveson IW et al, both published August 8, 2016, in the journal Nature Methods.
Related Links:
Garvan Institute of Medical Research
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







